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taking	part	 in	a	phase	 III	 study.	The	 incidences	of	 leukopenia	 (odds	ratio	 [OR]	1.9;	
P = .015),	neutropenia	(OR	2.2;	P = .002),	nausea	(OR	2.0;	P = .009),	and	vomiting	(OR	
2.8; P < .001)	were	increased	in	women	versus	men	treated	with	SOX,	while	vomiting	
(OR	2.9;	P < .001)	and	stomatitis	(OR	1.8;	P = .043)	were	increased	in	women	versus	
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1  | INTRODUC TION




















not	 only	 been	observed	 for	5‐FU	 treatment,	 but	 also	 for	 cisplatin	
and	adriamycin,	and	in	other	anticancer	agents.9	Female	patients	had	
significantly	higher	rates	of	vomiting	and	nausea,	however	the	cause	

























2  | MATERIAL S AND METHODS
2.1 | Patients
The	G‐SOX	 trial	 was	 a	 randomized,	 open‐label,	 phase	 III	 study	
that	compared	the	efficacy	and	safety	of	the	SOX	and	CS	treat‐
ment	 regimens	 in	 patients	 with	 curatively	 unresectable,	 ad‐





















phase	 III	 study.	Further	 translational	 research	studies	are	warranted	 to	pursue	 the	
cause	of	this	difference.
K E Y W O R D S
fluorouracil,	gastric	cancer,	oxaliplatin,	S‐1,	sex
























and	 those	 of	male	 patients	were	 75.8	mL/min	 (33.7‐189.2	mL/




P a Male (n = 257) Female (n = 81) Male (n = 243) Female (n = 92)
n % n % n % n %
Age
	<65 111 43.2 42 51.9 .201 109 44.9 53 57.6 .038
	≥65 146 56.8 39 48.1 134 55.1 39 42.4
ECOG	performance	status
 0 183 71.2 56 63.5 .414 177 72.8 59 64.1 .109
 1 72 28.0 23 28.4 62 25.5 33 35.9
 2 2 0.8 2 2.5 4 1.6 0 0
Unresectable 207 80.5 71 87.7 .182 199 81.9 78 84.8 .628
Recurrent 50 19.5 10 12.3 44 18.1 14 15.2
	Adjuvant	chemotherapy	(+) 24 9.3 7 8.6 20 8.2 9 9.8
	Adjuvant	chemotherapy	(‐) 26 10.1 3 3.7 24 9.9 5 5.4
Tumor	histology
	Differentiated	type 125 48.6 29 35.8 .055 119 49.0 29 31.5 .005
	Undifferentiated	type 132 51.4 52 64.2 124 51.0 63 68.5
Primary	tumor
	‐ 66 25.7 13 16.0 .097 62 25.5 17 18.5 .196
	+ 191 74.3 68 84.0 181 74.5 75 81.5
No.	of	metastatic	sites
 1 87 33.9 22 27.2 .377 78 32.1 26 28.3 .455
 2 105 40.9 33 40.7 107 44.0 36 39.1
	≥3 59 23.0 24 29.6 57 23.5 27 29.3
Metastatic	site	b 
	Liver 104 40.5 22 27.2 101 41.6 30 32.6
	Lung 32 12.5 5 6.2 27 11.1 8 8.7
	Lymph	node 225 87.5 74 91.4 214 88.1 79 85.9
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min)	and	79.4	mL/min	(41.1‐151.2	mL/min),	respectively.	Female	
patients	 treated	 with	 SOX	 developed	 leukopenia,	 neutropenia,	
nausea,	 and	 vomiting	 significantly	 more	 frequently	 than	 male	
patients,	while	women	 treated	with	CS	 demonstrated	 vomiting	
and	stomatitis	in	the	1st	treatment	cycle	more	often,	regardless	
of	 renal	 function,	 as	 compared	with	men.	 In	 contrast,	male	 pa‐
tients	undergoing	CS	therapy	experienced	thrombocytopenia	in	
the	1st	cycle	more	often	compared	with	female	patients.	Sex	was	
TA B L E  3  Multivariate	analyses	for	adverse	events	during	the	first	cycle	of	treatment	with	S‐1	plus	oxaliplatin	and	S‐1	plus	cisplatin
 Leukopenia Neutropenia Thrombocytopenia Nausea Vomiting Diarrhea Stomatitis
S‐1	plus	oxaliplatin
	Sex,	female	vs	male
	OR,	95%	CI 1.9,	1.1‐3.3 2.2,	1.3‐3.7 0.70,	0.39‐1.32 2.0,	1.2‐3.3 2.8,	1.6‐4.9 1.3,	0.78‐2.3 0.73,	0.28‐1.9
 P‐value .015 .0036 .25 .0096 .0004 .30 .51
	CCr,	70	mL/min≤	vs	70	mL/min>
	OR,	95%	CI 0.78,	0.43‐1.4 0.55,	0.31‐0.97 0.82,	0.43‐1.5 0.94,	0.55‐1.6 0.68,	0.35‐1.3 0.56,	0.32‐1.0 0.52,	0.20‐1.3
 P‐value .41 .039 .53 .83 .25 .053 .17
	BMI,	median≤	vs	median	>	per	sex
	OR,	95%	CI 0.72,	0.43‐1.2 0.81,	0.50‐1.3 1.2,	0.67‐2.0 0.76,	0.48‐1.2 0.85,	0.48‐1.5 1.3,	0.78‐2.1 1.2,	0.55‐2.8
 P‐value .20 .40 .61 .26 .59 .33 .60
	Age,	70≤	vs	70>
	OR,	95%	CI 0.91,	0.50‐1.6 0.63,	0.36‐1.1 0.64,	0.34‐1.2 1.1,	0.63‐1.9 0.77,	0.40‐1.5 0.95,	0.53‐1.7 1.0,	0.41‐2.6
 P‐value .75 .12 .18 .79 .45 .86 .93
	PS,	1,	or	2	vs	0
	OR,	95%	CI 0.90,	0.53‐1.5 0.60,	0.36‐1.0 0.92,	0.53‐1.6 0.92,	0.57‐1.5 1.8,	1.0‐3.1 1.1,	0.63‐1.8 2.0,	0.90‐4.3
 P‐value .69 .057 .78 .75 .040 .84 .088
	Peritoneal	dissemination,	yes	vs	no
	OR,	95%	CI 0.97,	0.53‐1.8 1.1,	0.62‐1.9 1.1,	0.58‐2.1 1.3,	0.74‐2.3 0.80,	0.40‐1.6 1.3,	0.75‐2.4 1.4,	0.56‐3.5
 P‐value .92 .75 .78 .36 .52 .32 .47
	S‐1	plus	cisplatin
	Sex,	female	vs	male
	OR,	95%	CI 0.98,	0.60‐1.6 0.66,	0.40‐1.1 0.52,	0.31‐0.88 1.4,	0.86‐2.3 2.8,	1.7‐4.9 1.5,	0.87‐2.4 1.9,	1.1‐3.4
 P‐value .94 .11 .014 .17 .0001 .15 .022
	CCr,	70	mL/min≤	vs	70	mL/min>
	OR,	95%	CI 0.59,	0.36‐0.99 0.60,	0.35‐1.0 0.78,	0.47‐1.3 0.74,	0.44‐1.2 0.55,	0.31‐0.98 0.91,	0.54‐1.6 0.94,	0.52‐1.7
 P‐value .044 .06 .35 .25 .042 .74 .84
	BMI,	median≤	vs	median	>	per	sex
	OR,	95%	CI 0.67,	0.42‐1.1 0.53,	0.33‐0.85 0.83,	0.52‐1.3 1.2,	0.76‐1.9 0.85,	0.49‐1.5 0.68,	0.42‐1.1 0.77,	0.44‐1.3
 P‐value 0.086 0.0084 0.43 0.44 0.55 0.12 0.34
	Age,	≤70	vs	>70	years
	OR,	95%	CI 1.3,	0.77‐2.2 0.98,	0.57‐1.7 1.9,	1.1‐3.2 0.84,	0.51‐1.4 1.1,	0.59‐1.9 1.2,	0.72‐2.1 1.8,	1.0‐3.2
 P‐value .33 .94 .016 .51 .85 .46 .045
	PS,	1,	or	2	vs	0
	OR,	95%	CI 1.0,	0.60‐1.6 1.5,	0.87‐2.4 0.89,	0.54‐1.5 1.1,	0.67‐1.8 1.1,	0.60‐1.9 1.4,	0.84‐2.3 1.3,	0.74‐2.3
 P‐value .91 .15 .64 .71 .86 .20 .36
	Peritoneal	dissemination,	yes	vs	no
	OR,	95%	CI 1.6,	0.91‐2.8 0.93,	0.53‐1.7 1.0,	0.59‐1.8 1.5,	0.85‐2.6 1.2,	0.65‐2.3 0.76,	0.42‐1.4 0.82,	0.41‐1.6
 P‐value .11 .81 .91 .16 .54 .38 .56
The	median	BMI	of	female	patients	treated	with	S‐1	plus	oxaliplatin	or	S‐1	plus	cisplatin	were	20.4	kg/m2,	and	the	BMI	of	males	were	21.6	kg/m2.
Abbreviations:	BMI,	body	mass	index;	CCr,	creatinine	clearance;	CI,	confidence	interval;	OR,	odds	ratio;	PS,	performance	status.
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an	 independent	 predictive	marker	 of	 those	 toxicities	 (Table	 3).	











women	 and	men	 (P = 1.0).	The	 incidence	of	vomiting	 (39%;	 28/72)	
in	women	was	 significantly	 higher	 than	 that	 in	men	 (18%;	 41/233)	
(P = .0003)	in	the	SOX	group	when	aprepitant	was	not	given	(Table	4).	
The	mean	relative	dose	intensities	(RDIs)	for	S‐1	during	the	three	cy‐







for	CS	 (HR	0.812,	 95%	CI	 0.577‐1.143;	P = .233)	 (Figure	 1),	while	
the	median	PFS	was	5.5	mo	for	SOX	and	4.1	mo	for	CS	(HR	0.877,	



























induced	 by	 5‐FU	 would	 be	 more	 variable	 compared	 with	 oxalipl‐
atin	 treatment.	Despite	 the	observed	differences	between	 female	
patients	and	male	patients	of	 these	 toxicities,	 their	cause	was	not	
clearly	explained	from	this	study	on	its	own.
5‐Fluorouracil	 clearance	 is	 significantly	 lower	 in	 women	
than	 in	men	regardless	of	patient	age	and	the	given	5‐FU	dose.2 
Plasma	 samples	 from	 the	 1st	 cycle	 of	 391	 female	 patients	 and	
536	male	 patients	 treated	with	 a	 2400	mg/m2	 continuous	 infu‐
sion	of	5‐FU	over	44‐48	h	were	tested	for	5‐FU.	These	analyses	
indicated	that,	when	comparing	the	proposed	optimal	area	under	
the	plasma	drug	concentration‐time	curve	 (AUC)	 target	 range	of	
20‐30	 mg	 h/L,	 women	 received	 supraoptimal	 doses	 compared	
with	 men	 (P = .0083).16	 This	 higher	 plasma	 5‐FU	 concentration	
was	significantly	related	to	severer	neutropenia	and	stomatitis.17 
More	than	80%	of	a	given	dose	of	5‐FU	is	rapidly	catabolized	to	
dihydrofluorouracil	 by	DPD,	 the	 rate‐limiting	 enzyme	 of	 pyrimi‐
dine	metabolism,	and	to	 inactive	dihydrouracil.7	Toxicity	 from	5‐
FU	 in	women	was	 found	 in	a	 recent	 study	 to	be	 independent	of	
DPYD	 genotype.	 Female	 patients	 had	 a	 two‐fold	 higher	 risk	 for	
severe	 5‐FU‐related	 toxicity	 compared	 with	 male	 patients	 and	
toxicity	 in	women	was	 independent	 of	DPYD	 genotype	 because	




not	 reveal	 any	 sex‐related	differences.	Evidence	 for	methylation	
of	 the	DPYD	 promotor	 in	 the	 same	DNA	 from	 the	 same	 human	
liver	was	not	found.5	Pretherapeutic	dihydrouracil	concentration	
was	significantly	higher	in	female	colorectal	cancer	patients	com‐
pared	with	male	 patients,	 however	 the	dihydrouracil/uracil	 ratio	
did	 not	 differ	 according	 to	 sex.	 A	 high	 level	 of	 uracil	 in	 females	






n % n % P
Nausea
	SOX No 41 57 94 40 .015
Yes 5 56 9 38 .44
	CS No 14 58 32 52 .64
Yes 41 60 91 50 .20
Vomiting
	SOX No 28 39 41 18 .0003
Yes 2 22 4 17 1.0
	CS No 13 54 15 24 .011
Yes 25 37 33 18 .0038






bined	 OR,	 5.51;	 P = .0013),	 the	 common	 TYMS	 polymorphism	
5′VNTR2R/3R	 (47%),	 and	 a	 3′UTR	 6‐bp	 Indel	 (31%)	 (combined	
OR,	1.31;	P = 9.4 × 10−6).8	The	higher	 incidence	of	5‐FU‐related	
toxicities	 is	 difficult	 to	 explain	 by	 these	 rare	 DPYD	 variants.	 In	
total,	3‐5%	of	Caucasians	have	reduced	DPD	activity,18 however 
DPYD	 variants	 in	 the	 Japanese	 population	 are	 somewhat	 differ‐
ent	from	the	previously	reported	Caucasian	variants.	DPYD alleles 
2303C>A	and	103G>T	might	play	important	roles	in	5‐FU‐related	
toxicity	 for	 Japanese	patients.19	The	sensitivity	of	DPYD	 genetic	
testing	depends	on	the	number	of	variants	investigated.	By	com‐
bining	the	DPYD	variants	c.1905	+	1G>A	(also	known	as	DPYD *	2A,	
IVS14	 +	 1G>A),	 c.2846A>T,	 c.1679T>G,	 c.1129‐5923C>G,	 the	
20%‐30%	 rate	of	 early‐onset	5‐fluorouracil	 toxicities	 can	be	 ex‐
plained.20,21	 Patients	 without	 a	 DPYD	 decreased/no	 function	
variant	may	still	experience	severe	toxicity	due	to	other	genetic,	
environmental,	or	other	factors.21
Tegafur	 is	 converted	 to	 5‐FU	 mainly	 by	 CYP2A6,	 and	 poly‐
morphisms	 in	 CYP2A6	 are	 thought	 to	 be	 related	 to	 5‐FU	 toxic‐
ity.22	 In	 addition,	 previous	 studies	 have	 suggested	 that	CYP2A6	
activity	is	higher	in	women	and	could	be	induced	by	estradiol	via	
ERα,	although	further	studies	are	required	to	confirm	this	sugges‐
tion.23	 Sex	differences	are	well	 known	 in	disease	manifestations	
and	 treatment	 effects	 such	 as	 in	 autoimmune	 or	 cardiovascular	
diseases,	 and	 reaction	 to	vaccines.	Despite	 these	 insights,	 the	X	
chromosome	 is	 scrutinized	 less	 often	 in	 the	 current	 era	 of	 pop‐
ulation	 genetics	 analyses	 due	 to	 unique	 statistical	 challenges,24 
although	 genome	 analyses	 of	 sex	 chromosomes	 could	 resolve	
some	 profound	 medical	 questions	 such	 as	 described	 here.	 The	
reason	for	the	higher	incidence	of	thrombocytopenia	in	male	pa‐
tients	 treated	with	CS	 therapy	 could	 not	 be	 clearly	 understood.	
Thrombocytopenia	 after	 CS	was	 not	 correlated	with	 body	mass	
index,	this	result	differed	from	that	of	a	previous	study	on	cispla‐
tin‐based	therapy.11











Male Female Male Female
(n = 221) (n = 73) (n = 221) (n = 81)
S‐1
	RDI	(%) Median 83.7 75.0 .029a 83.3 83.3 .411a
 [Range] [17.0‐114.5] [13.0‐100]  [2.4‐112.9] [11.9‐101.7]  
 Mean,	SD 81.4,	20.6 75.4,	21.6 .032b 79.6,	22.7 84.0,	18.0 .081b
Oxaliplatin/cisplatin
	RDI	(%) Median 98.3 75.0 .077a 87.5 87.5 .958a
 [Range] [0‐100] [28.0‐100]  [0‐134.6] [0‐102.9]  





TA B L E  6  Reasons	for	dose	reduction	of	oxaliplatin	in	S‐1	plus	
oxaliplatin	(SOX)
Dose reduction of oxaliplatina
Male Female
(n = 257) (n = 81)




40 15.6 12 14.8
Thrombocytopenia:	<25	000/
mm3	(Grade	4)
2 0.8 0 0
Thrombocytopenia:	platelet	
transfusion	was	performed
1 0.4 0 0
Neutropenia:	<500/mm3 
(Grade	4)





0 0 1 1.2
Diarrhea:	≥Grade	3 10 3.9 4 4.9
Stomatitis:	≥Grade	3 1 0.4 0 0
Sensory	neuropathy	(Grade	2) 33 12.8 7 8.6
Investigator's	judgment 59 23.0 23 28.4
aPatients	can	be	included	in	more	than	one	category.	
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